Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression

Author:

Cheang Maggie C.U.12,Martin Miguel3,Nielsen Torsten O.4,Prat Aleix5,Voduc David6,Rodriguez-Lescure Alvaro7,Ruiz Amparo8,Chia Stephen6,Shepherd Lois9,Ruiz-Borrego Manuel10,Calvo Lourdes11,Alba Emilio12,Carrasco Eva13,Caballero Rosalia13,Tu Dongsheng9,Pritchard Kathleen I.14,Levine Mark N.15,Bramwell Vivien H.16,Parker Joel117,Bernard Philip S.18,Ellis Matthew J.19,Perou Charles M.117,Di Leo Angelo20,Carey Lisa A.1

Affiliation:

1. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, USA;

2. Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom;

3. Servicio de Oncología Médica, Instituto de Investigacion Sanitaria Hospital Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, Madrid, Spain;

4. Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada;

5. Translation Genomics Unit, Vall d´Hebron Institute of Oncology, Barcelona, Spain;

6. British Columbia Cancer Agency, Vancouver, British Columbia, Canada;

7. Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain;

8. Department of Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain;

9. National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada;

10. Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain;

11. Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain;

12. Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain;

13. GEICAM, Madrid, Spain;

14. Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada;

15. McMaster University, Hamilton, Ontario, Canada;

16. Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada;

17. Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA;

18. Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA;

19. Department of Medicine, Washington University, St. Louis, Missouri, USA;

20. Department of Oncology, Hospital of Prato, Istituto Toscani Tumori, Florence, Italy

Abstract

Abstract Purpose. To determine intrinsic breast cancer subtypes represented within categories defined by quantitative hormone receptor (HR) and HER2 expression. Methods. We merged 1,557 cases from three randomized phase III trials into a single data set. These breast tumors were centrally reviewed in each trial for quantitative ER, PR, and HER2 expression by immunohistochemistry (IHC) stain and by reverse transcription-quantitative polymerase chain reaction (RT-qPCR), with intrinsic subtyping by research-based PAM50 RT-qPCR assay. Results. Among 283 HER2-negative tumors with <1% HR expression by IHC, 207 (73%) were basal-like; other subtypes, particularly HER2-enriched (48, 17%), were present. Among the 1,298 HER2-negative tumors, borderline HR (1%–9% staining) was uncommon (n = 39), and these tumors were heterogeneous: 17 (44%) luminal A/B, 12 (31%) HER2-enriched, and only 7 (18%) basal-like. Including them in the definition of triple-negative breast cancer significantly diminished enrichment for basal-like cancer (p < .05). Among 106 HER2-positive tumors with <1% HR expression by IHC, the HER2-enriched subtype was the most frequent (87, 82%), whereas among 127 HER2-positive tumors with strong HR (>10%) expression, only 69 (54%) were HER2-enriched and 55 (43%) were luminal (39 luminal B, 16 luminal A). Quantitative HR expression by RT-qPCR gave similar results. Regardless of methodology, basal-like cases seldom expressed ER/ESR1 or PR/PGR and were associated with the lowest expression level of HER2/ERBB2 relative to other subtypes. Conclusion. Significant discordance remains between clinical assay-defined subsets and intrinsic subtype. For identifying basal-like breast cancer, the optimal HR IHC cut point was <1%, matching the American Society of Clinical Oncology and College of American Pathologists guidelines. Tumors with borderline HR staining are molecularly diverse and may require additional assays to clarify underlying biology.

Funder

National Cancer Institute

Strategic Partnering to Evaluate Cancer Signatures

NCI Breast SPORE program

Breast Cancer Research Foundation

FEDER

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3